Medicine Shoppe Pharmacy Recalls Levothyroxin/Liothyronine Capsules Due to Processing Control Issues
The Medicine Shoppe Pharmacy is recalling Levothyroxin/Liothyronine SR capsules due to a lack of processing control. The affected product was distributed in Florida.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric, particularly given the nature of the product and the stated lack of processing control.
Plain-English summary
The Medicine Shoppe Pharmacy in Port Charlotte, Florida, is recalling Levothyroxin (T4)/Liothyronine (T3) SR 130 mg/175 mg capsules. The recall is being conducted due to a lack of processing control. The affected product consists of 21-capsule bottles, with lot number 45274 and a discard-by date of 9/27/2020.
The recall is classified as Class II by the FDA. The product was distributed in Florida. No specific illnesses or injuries are reported in the source text.
Consumers who have this product should contact their healthcare provider or the pharmacy for further instructions on how to proceed.
The recalled product
- Product
- Levothyroxin (T4)/Liothyronine (T3) SR 130 mg/175 mg capsule 21 capsules bottle, Rx, The Medicine Shoppe Pharmacy, Port Charlotte, FL
- Manufacturer
- The Medicine Shoppe Pharmacy
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 45274 Discard by: 9/27/2020
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 54 recalled by The Medicine Shoppe Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 54 products in this recall →Related recalls
Same manufacturer · The Medicine Shoppe Pharmacy
See all →- SevereBi-Est Cream Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- ModerateDiethylstilbestrol Capsules Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- ModerateHydrocortisone Cream Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- ModerateTestosterone Gel Recalled by Florida Pharmacy for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- ModerateParegoric Alternate Elixir Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
Same hazard · processing control
See all →- ModerateErgotamine Tartrate and Caffeine Suppositories Recalled for Processing Control Issues
FDA (Drugs) · 2020-04-22
- ModerateEstradiol Vaginal Cream Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
Similar recalls
- ModerateMedical Park Pharmacy Recalls Liothyronine Capsules Due to Expired Components
FDA (Drugs) · 2020-02-05
- CriticalFDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
FDA (Drugs) · 2018-08-29
- CriticalFDA Recalls Levothyroxine and Liothyronine Thyroid Tablets Due to Content Uniformity Failures
FDA (Drugs) · 2018-08-29
- SevereMoore's Compounding Pharmacy Recalls Levothyroxine/Liothyronine Capsules for Potency Failures
FDA (Drugs) · 2017-03-01
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- ModerateReliable Drug Recalls T4-Levothyroxine Products Due to Processing Control Deficiencies
FDA (Drugs) · 2016-07-13